Šalis: Didžioji Britanija
kalba: anglų
Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)
Nebivolol hydrochloride
DE Pharmaceuticals
C07AB12
Nebivolol hydrochloride
10mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
Package leaflet: Information for the patient (Nebivolol) NEBIVOLOL 10 MG TABLETS WHAT IS IN THIS LEAFLET 1. What Nebivolol Tablets is and what it is used for 2. What you need to know before you take Nebivolol Tablets 3. How to take Nebivolol Tablets 4. Possible side effects 5. How to store Nebivolol Tablets 6. Contents of the pack and other information 1. WHAT NEBIVOLOL TABLETS IS AND WHAT IT IS USED FOR Nebivolol Tablets (also referred to as Nebivolol throughout this leaflet) contains nebivolol, a cardiovascular drug belonging to the group of selective beta-blocking agents (i.e. with a selective action on the cardiovascular system). It prevents increased heart rate, controls heart pumping strength. It also exerts a dilating action on blood vessels, which contributes as well to lower blood pressure. It is used to treat raised blood pressure (hypertension). Nebivolol Tablets is also used to treat mild and moderate chronic heart failure in patients aged 70years or over, in addition to other therapies. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NEBIVOLOL TABLETS DO NOT TAKE NEBIVOLOL TABLETS: • If you are allergic to nebivolol or any of the other ingredients of this medicine (listed in section 6). • If you have one or more of the following disorders: o low blood pressure o serious circulation problems in the arms or legs o very slow heartbeat (less than 60 beats per minute) o certain other serious heart rhythm problems (e.g. 2nd and 3rd degree atrioventricular block, heart conduction disorders). • heart failure, which has just occurred, or which has recently become worse, or you are receiving treatment for circulatory shock due to acute heart failure by intravenous drip feed to help your heart work. • asthma or wheezing (now or in the past), untreated phaeochromocytoma, a tumour located on top of the kidneys (in the adrenal glands) • liver function disorder • a metabolic disorder (metabolic acidosis), for example, diabetic ketoacidosis. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taki Perskaitykite visą dokumentą
OBJECT 1 NEBIVOLOL 10MG TABLETS Summary of Product Characteristics Updated 13-Mar-2019 | Glenmark Pharmaceuticals Europe Ltd • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Nebivolol 10 mg Tablets 2. Qualitative and quantitative composition Each tablet contains 10.90 mg nebivolol hydrochloride corresponding to 10 mg nebivolol Excipient(s) with known effect: 139.55 mg of lactose monohydrate/tablet For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet 10 mg: Circular, white, shallow, biconvex uncoated tablets engraved with 'G' and 'N' on either side of break line on one side and plain on other side. The tablet can be divided into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Hypertension Treatment of essential hypertension Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients > 70 years. 4.2 Posology and method of administration Posology Hype Perskaitykite visą dokumentą